within Pharmacolibrary.Drugs.ATC.N;

model N05AB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.12,
    Cl             = 0.05,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.0106,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00475,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Prochlorperazine is a dopamine (D2) receptor antagonist from the phenothiazine class. It is primarily used in the management of severe nausea and vomiting, as well as for the treatment of schizophrenia and anxiety. Prochlorperazine remains approved and in clinical use today, particularly as an antiemetic.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Hoy, SM, &amp; Scott, LJ (2011). Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache. <i>CNS drugs</i> 25(4) 343–358. DOI:<a href=&quot;https://doi.org/10.2165/11206740-000000000-00000&quot;>10.2165/11206740-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21425885/&quot;>https://pubmed.ncbi.nlm.nih.gov/21425885</a></p></li><li><p>Zhang, H, et al., &amp; Streisand, JB (2002). Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. <i>Clinical pharmacokinetics</i> 41(9) 661–680. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200241090-00003&quot;>10.2165/00003088-200241090-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12126458/&quot;>https://pubmed.ncbi.nlm.nih.gov/12126458</a></p></li><li><p>Taylor, WB, &amp; Bateman, DN (1987). Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. <i>British journal of clinical pharmacology</i> 23(2) 137–142. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1987.tb03021.x&quot;>10.1111/j.1365-2125.1987.tb03021.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3828192/&quot;>https://pubmed.ncbi.nlm.nih.gov/3828192</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AB04;
